Clinical Trial Update: Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial update for orvepitant (GW823296) in adults with post-traumatic stress disorder. The study has been completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Orvepitant (Orvepitant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Post-Traumatic Stress Disorder | Phase 2 | Status: COMPLETED | Results posted: 2017-09-01